William Blair Reaffirms Outperform Rating for Alnylam Pharma

William Blair reiterated their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report released on Monday, RTT News reports. ALNY has been the subject of several other reports. JPMorgan Chase & Co. boosted their target price on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company […]

Related Keywords

William Blair , Jpmorgan Chase Co , Harbor Capital Advisors Inc , Analyst Recommendations For Alnylam Pharmaceuticals , Alnylam Pharmaceuticals Stock Down , News Ratings For Alnylam Pharmaceuticals Daily , Alnylam Pharmaceuticals , Ep Wealth Advisors , Citigroup , Steward Partners Investment Advisory , Alnylam Pharmaceuticals Inc , Wells Fargo Company , Morgan Stanley , Bridgewater Associates , Free Report , Moderate Buy , Pharmaceuticals Stock Down , Get Free Report , Capital Advisors , Financial Advisors , Partners Investment Advisory , Alnylam Pharmaceuticals Daily ,